CytomX Therapeutics, Inc. (NASDAQ:CTMX) Sees Significant Increase in Short Interest

CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 5,540,000 shares, a growth of 26.2% from the November 30th total of 4,390,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is presently 4.8 days.

CytomX Therapeutics Price Performance

Shares of CytomX Therapeutics stock opened at $1.02 on Tuesday. CytomX Therapeutics has a 1 year low of $0.83 and a 1 year high of $5.85. The company has a market capitalization of $79.82 million, a price-to-earnings ratio of 6.00 and a beta of 1.07. The business has a fifty day simple moving average of $1.05 and a two-hundred day simple moving average of $1.18.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.23. The business had revenue of $33.43 million during the quarter, compared to the consensus estimate of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same quarter in the previous year, the firm posted $0.04 EPS. As a group, equities analysts anticipate that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CytomX Therapeutics

Large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in CytomX Therapeutics in the 3rd quarter valued at $104,000. Geode Capital Management LLC boosted its position in shares of CytomX Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 34,032 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in shares of CytomX Therapeutics by 1.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after acquiring an additional 16,359 shares in the last quarter. FMR LLC increased its position in CytomX Therapeutics by 17.3% during the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock worth $335,000 after acquiring an additional 41,949 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in CytomX Therapeutics by 10.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after purchasing an additional 26,373 shares in the last quarter. Institutional investors own 67.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Monday, November 11th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, CytomX Therapeutics has an average rating of “Hold” and an average target price of $5.77.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.